news aktuell GmbH

Visable GmbH: Applegate and Visable: B2B platform providers forge strategic partnership to strengthen international trade of UK-based businesses

22.9.2021 15:22:17 CEST | news aktuell GmbH | Press release

Share
Paris / Hamburg / Barnstaple, 22 September 2021 – Visable, the parent company of Europe’s leading online B2B platforms EUROPAGES and wlw (formerly "Wer liefert was"), and Applegate, the premier B2B marketplace in the United Kingdom, have entered into an exclusive partnership. As the official reselling partner in the UK, Applegate is able to offer listings and additional online marketing services on EUROPAGES and wlw alongside its own AI-based sourcing platform. As a result, companies in the UK benefit from greater visibility on the web to promote their products and services to procurement professionals across Europe.

(Paris / Hamburg / Barnstaple): “We are delighted to announce our partnership with Applegate. Both companies are driven by a common mission, which is to connect international B2B purchasers with matching suppliers,” says Visable CEO Peter F. Schmid. “After Germany, the UK is the second largest economy in Europe. We are convinced that Applegate’s strong local footprint, market expertise and salesforce will allow us to further increase our market share, while providing UK-based businesses with a unique opportunity to expand their reach across Europe and beyond.”

The goal of the partnership is to maximise British companies’ visibility on the web and to boost international trade by making their portfolios available to purchasers in 15 languages.
By extending their marketing mix to include profiles on EUROPAGES and wlw, Applegate customers can present their products and services to an additional four million international procurement professionals on top of the over 18,000 purchasers that already use the UK’s premier AI-driven B2B platform.

Stuart Brocklehurst, Chief Executive at Applegate, explains, “We have long admired Visable’s incredible work promoting business connections across the continent. It’s great to partner with them to bring this to the UK. Together, Applegate and Visable provide a winning combination for businesses seeking growth.”

The partnership enables Applegate to support UK companies’ digital marketing efforts and visibility on the European mainland after Brexit while allowing Visable to further pursue its internationalisation strategy with a strong partner in the UK.

Contacts

achtung!
Ingrid Lisica
+4940450210-737
visable@achtung.de

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:43:52 CET | Press release

Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.

Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:02 CET | Press release

(Berlin, Germany) A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative Around 11 million tonnes of plastic waste enter the oceans every year. Without effective countermeasures, this volume could almost triple by 2040. Studies show that about 80 percent of marine plastic reaches the sea via roughly 1,656 rivers worldwide. To date, everwave has removed more than 2.4 million kilograms of plastic from rivers in Cambodia, Albania, and Thailand. The company uses waste collection boats, barriers, and manual cleanups to stop plastic before it reaches the oceans. At the same time, mobile sorting and recycling solutions return materials efficiently to the circular economy. AI support optimizes collection routes to clean as many waterways as possible in a sustainable wa

Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:52:51 CET | Press release

Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye